Asset
EGANELISIB
Arcus Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03719326 | phase1 | completed | 2018-10-15 | 2021-07-01 | Arcus Biosciences, Inc. | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies |
FDA applications (0)
This company has no applications containing this asset.